Market Cap 1.87B
Revenue (ttm) 2.78B
Net Income (ttm) -2.05B
EPS (ttm) N/A
PE Ratio 13.04
Forward PE 11.74
Profit Margin -73.74%
Debt to Equity Ratio 0.83
Volume 540,214
Avg Vol 1,516,418
Day's Range N/A - N/A
Shares Out 67.63M
Stochastic %K 39%
Beta 0.10
Analysts Sell
Price Target $47.14

Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, ant...

Industry: Medical Devices
Sector: Healthcare
Phone: 858 552 1100
Fax: 858 453 4338
Address:
9975 Summers Ridge Road, San Diego, United States
smartkarma
smartkarma Jun. 25 at 5:04 AM
$QDEL | QuidelOrtho Corporation Is Executing A Billion-Dollar Manufacturing Overhaul; What Is The Expected Revenue Impact? "QuidelOrtho's latest earnings provides insight into the company's performance and strategic direction. For the first quarter of 2025, QuidelOrtho..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/quidelortho-corporation-is-executing-a-billion-dollar-manufacturing-overhaul-what-is-the-expected-revenue-impact
0 · Reply
ZacksResearch
ZacksResearch Jun. 24 at 4:39 PM
$QDEL: After a 37.9% YTD drop, is this diagnostic company poised for a comeback? 📈 🩺 Strong Q1 results driven by Labs, Immunohematology, and Molecular Diagnostics segments 🧬 Expanding product portfolio, including FDA-approved Savanna system 📊 Positive earnings estimate revision trend for 2025, despite risks from overdependence on respiratory segment and reimbursement policies Discover the full growth potential here 👉 https://www.zacks.com/commentary/2545042/reasons-to-retain-quidelortho-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2545042-body&ADID=SYND_STOCKTWITS_TWEET_2_2545042_BODY
0 · Reply
ZacksResearch
ZacksResearch Jun. 24 at 2:55 PM
$QDEL — Why I’m holding, not folding The company’s solid product lineup is still driving growth, giving it staying power in this market. Full breakdown on why QDEL still earns a spot in the portfolio 👉 https://www.zacks.com/stock/news/2545042/reasons-to-retain-quidelortho-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2545042-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2545042_TEASER
0 · Reply
yurched
yurched Jun. 13 at 11:00 AM
$QDEL 💀 DEBT BOMB
0 · Reply
StockBraker
StockBraker Jun. 9 at 12:18 PM
$QDEL 6-10 minute testing using patented thermal cycling technology.
0 · Reply
OpenOutcrier
OpenOutcrier Jun. 4 at 11:45 AM
$QDEL (-4.3% pre) QuidelOrtho Makes Major Molecular Diagnostics Pivot: $100M LEX Acquisition to Replace Savanna Platform https://ooc.bz/l/66835
0 · Reply
DonCorleone77
DonCorleone77 Jun. 3 at 8:19 PM
$QDEL QuidelOrtho maintains FY25 guidance issued on February 12 Based on its current business outlook, the company is maintaining its fiscal 2025 financial guidance provided on February 12, 2025.
0 · Reply
DonCorleone77
DonCorleone77 Jun. 3 at 8:18 PM
$QDEL QuidelOrtho announces a refocusing of its molecular diagnostics strategy QuidelOrtho announced a refocusing of its molecular diagnostics strategy. This strategy includes the intent to acquire full ownership of LEX Diagnostics after 510(k) clearance by the U.S. FDA for consideration at closing of approximately $100M and plans to discontinue the company's Savanna platform development. In December 2023, QuidelOrtho invested in LEX Diagnostics, which included the exclusive option to acquire the company up to or shortly after 510(k) clearance by the FDA. LEX Diagnostics expects to submit dual 510(k) and CLIA-waiver applications to the FDA in the coming days and expects to receive 510(k) clearance in late 2025 or early 2026, depending on FDA review timelines. QuidelOrtho plans to discontinue its Savanna platform development. This decision reflects several factors, including the recent results of the Savanna RVP4X clinical trial. The company intends to work closely with its customers and partners to facilitate an orderly transition plan.
0 · Reply
OptionRunners
OptionRunners May. 30 at 7:19 PM
$QDEL Buyer of the September 19th $35/$25 bull risk reversals 3,000 times for $1.00
0 · Reply
Mina_Nashed
Mina_Nashed May. 30 at 5:55 PM
$QDEL No one Cares about paid bashers, Keep your opinion to yourself simp
0 · Reply
Latest News on QDEL
QuidelOrtho to Participate in Upcoming Investor Conferences

May 22, 2025, 4:30 PM EDT - 4 weeks ago

QuidelOrtho to Participate in Upcoming Investor Conferences


QuidelOrtho Reports First Quarter 2025 Financial Results

May 7, 2025, 4:05 PM EDT - 6 weeks ago

QuidelOrtho Reports First Quarter 2025 Financial Results


QuidelOrtho to Report First Quarter 2025 Financial Results

Apr 23, 2025, 4:30 PM EDT - 2 months ago

QuidelOrtho to Report First Quarter 2025 Financial Results


QuidelOrtho® Introduces Results Manager™ System

Mar 10, 2025, 9:00 AM EDT - 3 months ago

QuidelOrtho® Introduces Results Manager™ System


QuidelOrtho Corporation (QDEL) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 7:50 PM EST - 4 months ago

QuidelOrtho Corporation (QDEL) Q4 2024 Earnings Call Transcript


Carlyle Sells QuidelOrtho Shares, Analyst Sees Overhang Lifted

Nov 20, 2024, 3:08 PM EST - 7 months ago

Carlyle Sells QuidelOrtho Shares, Analyst Sees Overhang Lifted


Top 4 Health Care Stocks That May Plunge This Quarter

Nov 11, 2024, 6:18 AM EST - 8 months ago

Top 4 Health Care Stocks That May Plunge This Quarter

AIRS NUVB PODD


QuidelOrtho Corporation (QDEL) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 8:54 PM EST - 8 months ago

QuidelOrtho Corporation (QDEL) Q3 2024 Earnings Call Transcript


QuidelOrtho Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 4:05 PM EST - 8 months ago

QuidelOrtho Reports Third Quarter 2024 Financial Results


QuidelOrtho to Report Third Quarter 2024 Financial Results

Oct 17, 2024, 7:00 AM EDT - 8 months ago

QuidelOrtho to Report Third Quarter 2024 Financial Results


QuidelOrtho Announces New R&D Executive Leader

Oct 9, 2024, 7:00 AM EDT - 9 months ago

QuidelOrtho Announces New R&D Executive Leader


QuidelOrtho Appoints Lee Bowman as Chief Human Resources Officer

Sep 10, 2024, 7:00 AM EDT - 10 months ago

QuidelOrtho Appoints Lee Bowman as Chief Human Resources Officer


QuidelOrtho Corporation (QDEL) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 9:02 PM EDT - 11 months ago

QuidelOrtho Corporation (QDEL) Q2 2024 Earnings Call Transcript


QuidelOrtho Reports Second Quarter 2024 Financial Results

Jul 31, 2024, 4:05 PM EDT - 11 months ago

QuidelOrtho Reports Second Quarter 2024 Financial Results


QuidelOrtho to Report Second Quarter 2024 Financial Results

Jul 17, 2024, 7:00 AM EDT - 1 year ago

QuidelOrtho to Report Second Quarter 2024 Financial Results


smartkarma
smartkarma Jun. 25 at 5:04 AM
$QDEL | QuidelOrtho Corporation Is Executing A Billion-Dollar Manufacturing Overhaul; What Is The Expected Revenue Impact? "QuidelOrtho's latest earnings provides insight into the company's performance and strategic direction. For the first quarter of 2025, QuidelOrtho..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/quidelortho-corporation-is-executing-a-billion-dollar-manufacturing-overhaul-what-is-the-expected-revenue-impact
0 · Reply
ZacksResearch
ZacksResearch Jun. 24 at 4:39 PM
$QDEL: After a 37.9% YTD drop, is this diagnostic company poised for a comeback? 📈 🩺 Strong Q1 results driven by Labs, Immunohematology, and Molecular Diagnostics segments 🧬 Expanding product portfolio, including FDA-approved Savanna system 📊 Positive earnings estimate revision trend for 2025, despite risks from overdependence on respiratory segment and reimbursement policies Discover the full growth potential here 👉 https://www.zacks.com/commentary/2545042/reasons-to-retain-quidelortho-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2545042-body&ADID=SYND_STOCKTWITS_TWEET_2_2545042_BODY
0 · Reply
ZacksResearch
ZacksResearch Jun. 24 at 2:55 PM
$QDEL — Why I’m holding, not folding The company’s solid product lineup is still driving growth, giving it staying power in this market. Full breakdown on why QDEL still earns a spot in the portfolio 👉 https://www.zacks.com/stock/news/2545042/reasons-to-retain-quidelortho-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2545042-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2545042_TEASER
0 · Reply
yurched
yurched Jun. 13 at 11:00 AM
$QDEL 💀 DEBT BOMB
0 · Reply
StockBraker
StockBraker Jun. 9 at 12:18 PM
$QDEL 6-10 minute testing using patented thermal cycling technology.
0 · Reply
OpenOutcrier
OpenOutcrier Jun. 4 at 11:45 AM
$QDEL (-4.3% pre) QuidelOrtho Makes Major Molecular Diagnostics Pivot: $100M LEX Acquisition to Replace Savanna Platform https://ooc.bz/l/66835
0 · Reply
DonCorleone77
DonCorleone77 Jun. 3 at 8:19 PM
$QDEL QuidelOrtho maintains FY25 guidance issued on February 12 Based on its current business outlook, the company is maintaining its fiscal 2025 financial guidance provided on February 12, 2025.
0 · Reply
DonCorleone77
DonCorleone77 Jun. 3 at 8:18 PM
$QDEL QuidelOrtho announces a refocusing of its molecular diagnostics strategy QuidelOrtho announced a refocusing of its molecular diagnostics strategy. This strategy includes the intent to acquire full ownership of LEX Diagnostics after 510(k) clearance by the U.S. FDA for consideration at closing of approximately $100M and plans to discontinue the company's Savanna platform development. In December 2023, QuidelOrtho invested in LEX Diagnostics, which included the exclusive option to acquire the company up to or shortly after 510(k) clearance by the FDA. LEX Diagnostics expects to submit dual 510(k) and CLIA-waiver applications to the FDA in the coming days and expects to receive 510(k) clearance in late 2025 or early 2026, depending on FDA review timelines. QuidelOrtho plans to discontinue its Savanna platform development. This decision reflects several factors, including the recent results of the Savanna RVP4X clinical trial. The company intends to work closely with its customers and partners to facilitate an orderly transition plan.
0 · Reply
OptionRunners
OptionRunners May. 30 at 7:19 PM
$QDEL Buyer of the September 19th $35/$25 bull risk reversals 3,000 times for $1.00
0 · Reply
Mina_Nashed
Mina_Nashed May. 30 at 5:55 PM
$QDEL No one Cares about paid bashers, Keep your opinion to yourself simp
0 · Reply
East161stNY
East161stNY May. 29 at 9:12 PM
$QDEL from the looks of it you are a paid pumper like @secretcasino
1 · Reply
EZMONEY2025
EZMONEY2025 May. 22 at 5:51 PM
$QDEL closed short at 29.50. Nobody is buying this stock
2 · Reply
Chickenstick1
Chickenstick1 May. 21 at 7:01 PM
$QDEL Buying moree.
0 · Reply
Chickenstick1
Chickenstick1 May. 14 at 7:03 PM
$IWM Funds are indiscriminately selling anything with a leverage ratio, regardless of earnings, covenant agreements or projected FCF. I've made a killing trading the alpha in names like $NVEE, $QDEL on earnings because their revenue streams debt covenants are sound and not levered to every move in the 10year. At least once a quarter, WS is forced to reckon with reality and because they're lazy, they rinse and repeat. It doesnt take a lot of work to beat the street, because you'd be quite surprised how little actual Due diligence is done on the short side. Many boomer managers use motif ETFs or baskets provided by their brokerage.
0 · Reply
Chickenstick1
Chickenstick1 May. 13 at 8:02 PM
$QDEL Debt is priced on EBITDA, so the hedge funds selling this on 10 year action will continue to get busted.
0 · Reply
Chickenstick1
Chickenstick1 May. 13 at 8:00 PM
$QDEL ADDed into the close. $70 by YE.
0 · Reply
StockBraker
StockBraker May. 9 at 12:05 PM
$QDEL https://www.gurufocus.com/news/2844688/quidelortho-qdel-upgraded-to-buy-by-jefferies-qdel-stock-news
0 · Reply
im_ichiban
im_ichiban May. 9 at 10:51 AM
$EMBC Embecta Corp. (NASDAQ: EMBC) reported Q2 EPS of $0.70, $0.17 better than the analyst estimate of $0.53. Revenue for the quarter came in at $259 million versus the consensus estimate of $253.86 million. GUIDANCE: Embecta Corp. sees FY2025 EPS of $2.70-$2.90, versus the consensus of $2.82. Embecta Corp. sees FY2025 revenue of $1.07-1.09 billion, versus the consensus of $1.09 billion. $0.15 quarter dividend $BBNX $DXCM $QDEL
0 · Reply
Bazzzigar
Bazzzigar May. 9 at 12:25 AM
$QDEL tomorrow back to $25
0 · Reply
gvnbykplt1903
gvnbykplt1903 May. 8 at 11:28 PM
$QDEL $40 dollars more please
0 · Reply
dkbrooklyn
dkbrooklyn May. 8 at 7:54 PM
0 · Reply
topstockalerts
topstockalerts May. 8 at 7:44 PM
Top Movers pt 2 $DAVE $EBS $GRPN $QDEL $STI
0 · Reply